Origin Life Sciences

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

LFCR

ATNF

SBIO

LABU

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc. | BBCMF Stock News

StockTitan

Lifecore Biomedical

180 Life Sciences

iShares Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc. | BBCMF Stock News

NDRA

OLSI

MDLS

Denver Life Sciences announced that serial entrepreneur Mike Iiams has invested in the company and joined its board. DLS aims to address chronic dehydration, a health risk affecting 72 million Americans annually, by using advanced sensors to measure hydration levels in under 45 seconds. The company offers a modern alternative to outdated hydration measurement methods, providing personalized insights through a mobile app. Iiams, motivated by personal experiences, sees DLS's mission and technology as a significant advancement in health and wellness.

prnewswire

Endra Life Sciences

MDNA Life Sciences, Inc.

SPDR S&P Health Equip

iShares US Medical Devices

11:09 ETSerial Entrepreneur Invests in Hydration Mission

IBBQ

Emmaus Life Sciences Reports Annual Financial Results | EMMA Stock News

iShares Global Healthcare

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Emmaus Life Sciences Reports Annual Financial Results | EMMA Stock News

TLSA

Discovery Life Sciences and Mindpeak have formed a partnership to enhance cancer biomarker testing in global clinical trials using AI. This collaboration aims to address the inconsistent interpretation of biomarkers by pathologists, which has been a significant challenge in drug development. By integrating AI-driven digital image analysis into immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) services, the partnership seeks to improve biomarker quantification and consistency, thereby reducing variability and increasing confidence in critical development decisions. The partnership will be showcased at the AACR 2026 annual meeting.

Tiziana Life Sciences

12:05 ETPartnerství společností Discovery Life Sciences a Mindpeak vnáší přesnost AI do testování biomarkerů rakoviny v globálních klinických studiích

IDNA

Mabtech has formed a strategic collaboration with Sai Life Sciences, designating Sai's Boston site as a U.S. execution hub for its EYRA™ multiplex immunology platform. This partnership aims to enhance access to high-sensitivity multiplex immune profiling for biopharma and biotech clients. The collaboration will involve joint delivery of advanced immunology assay services, including multiplex cytokine profiling and custom panel development. Mabtech's EYRA platform will enable efficient immune profiling, supporting research in immuno-oncology, vaccines, and inflammation. The initiative also includes co-branded business development activities targeting U.S. biopharma companies.

Fidelity

iShares US Healthcare Providers

iShares Genomics Immunology and Healthcare ETF

Mabtech Establishes Strategic U.S. Collaboration with Sai Life Sciences to Expand Access to EYRAâ¢ Multiplex Immunology Platform

BRSHF

LABD

On March 2, 2026, in Mississauga, Ontario, BioSyent Inc. completed the acquisition of Oral Science Inc., a private Canadian distributor from Brossard, Quebec. Oral Science specializes in healthcare products for dental hygiene and oral health. BioSyent, listed on TSX Venture as RX, successfully closed the acquisition deal, marking a significant milestone for the company. This acquisition allows BioSyent to expand its portfolio and reach in the healthcare sector, further solidifying its position in the market.

Unusual Whales

BRUUSH ORAL CARE INC

Direxion S&P Biotech Bear 3X

Minsheng Royal CSI Biotechnology Theme ETF

KETOP

ChinaAMC CSI All Share Health Care Devices ETF

E Fund CSI Biotechnology Theme ETF

Intelligent Bio Solutions

Bosera Hang Seng Health Care ETF(QDII)

Hwabao WP CSI Medical Service ETF

ChinaAMC CSI Biotechnology Theme ETF

Imagion Biosystems Ltd Warrant 2019-21.11.21 On Imagion Biosyst

China Merchants CSI Biotechnology Theme ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

BioSyent Inc. completes acquisition of Oral Science Inc., a dental hygiene product distributor based in Quebec.

In Los Angeles on February 19, 2026, it was reported that there is a growing demand among men for alternative contraceptive methods beyond condoms and vasectomies. The focus is on non-hormonal options, with particular interest in long-acting reversible methods and short-term, on-demand solutions. NEXT Life...

Male birth control options in phase II trials offer non-hormonal methods for men beyond condoms and vasectomy.

NEXT Life Sciences has advanced two male contraceptive options, Plan A™ and NLS-133, into Phase II clinical trials. Plan A™ is a long-acting, non-hormonal, reversible-on-demand contraceptive, while NLS-133 is a non-hormonal pill providing 24 hours of protection. Both options aim to address the unmet need for male contraceptives, as current choices are limited to condoms and vasectomy. The company plans a Series A funding round in 2026 to support further development. With a significant demand for new contraceptive methods, NEXT Life Sciences is positioned as a leader in this innovative space.

15:22 ETTwo Male Birth Control Options Advance Into Phase II Clinical Trials

Notice of Pendency and Proposed Settlement of Stockholder Class Action for CM Life Sciences III, Inc. Class A Common Stock. A settlement of $7,250,000 has been proposed, affecting all record and beneficial holders of the stock as of December 14, 2021. A hearing is scheduled for April 21, 2026, to determine the approval of the settlement and related matters. Class members must submit a Proof of Claim to participate in the distribution of the settlement fund.

Caris Life Sciences

09:13 ETNotice of Pendency and Proposed Settlement of Stockholder Class Action Involving All Record and Beneficial Holders of CM Life Sciences III, Inc. Class A Common Stock on December 14, 2021

IDXX

BLAC

ETHZ

FRMM

LIR Life Sciences Corp. has initiated Project Phase 2 of its peptide design program in collaboration with Neuland Laboratories. This phase focuses on optimizing next-generation cell-penetrating peptides to enhance LIR's transdermal delivery platform. The program aims to identify synthetic variants that improve transport activity and manufacturability. CEO Edward Mills emphasized the importance of this phase in advancing their peptide development strategy, which seeks to provide scalable treatments for obesity through innovative drug delivery methods. The company is committed to addressing obesity with practical solutions based on established science.

IDEXX Labs

Bellevue Life Sciences Acquisition

Ethzilla

Forum Markets

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories | BBCMF Stock News

Origin Life Sciences(OLSI.US)

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc. | BBCMF Stock News

11:09 ETSerial Entrepreneur Invests in Hydration Mission

Emmaus Life Sciences Reports Annual Financial Results | EMMA Stock News

12:05 ETPartnerství společností Discovery Life Sciences a Mindpeak vnáší přesnost AI do testování biomarkerů rakoviny v globálních klinických studiích

Mabtech Establishes Strategic U.S. Collaboration with Sai Life Sciences to Expand Access to EYRAâ¢ Multiplex Immunology Platform

BioSyent Inc. completes acquisition of Oral Science Inc., a dental hygiene product distributor based in Quebec.

Male birth control options in phase II trials offer non-hormonal methods for men beyond condoms and vasectomy.

15:22 ETTwo Male Birth Control Options Advance Into Phase II Clinical Trials

09:13 ETNotice of Pendency and Proposed Settlement of Stockholder Class Action Involving All Record and Beneficial Holders of CM Life Sciences III, Inc. Class A Common Stock on December 14, 2021

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories | BBCMF Stock News